FDA Warns: Animal Drugs Could Supercharge Human Bacteria Threats
Published Date: 8/6/2026
Notice
Summary
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry (GFI) #152 entitled "Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern." This guidance document informs interested parties about FDA's current method for evaluating potential microbiological effects of antimicrobial new animal drugs on bacteria of human health concern as part of the new animal drug application process.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Final FDA Method for Drug Application Reviews
The FDA issued final Guidance for Industry (GFI) #152 describing the Agency's current method for evaluating potential microbiological effects of antimicrobial new animal drugs as part of the new animal drug application review process. The guidance was announced in the Federal Register on August 6, 2026.
Updated Appendix A Drug Importance Rankings
GFI #152 includes Appendix A rankings of medically important antimicrobial drugs into ‘critically important,’ ‘highly important,’ and ‘important’ for human medicine and states these rankings should inform one component of the risk assessment. The final guidance also explains why topical antimicrobials are excluded from the ranking.
Guidance Is Nonbinding; Alternatives Allowed
The guidance is Level 1 and represents FDA's current thinking, but it does not establish rights and is not binding on FDA or the public; you may use an alternative approach if it satisfies applicable statutes and regulations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19281, Agency Information Collection Activities; Proposed Collection; Comment Request; Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002
The FDA wants your thoughts on keeping the rules for telling them about imported food before it arrives. This affects food importers who must keep sharing info to keep our food safe. You’ve got until November 20, 2026, to send in your comments—no cost changes, just a chance to help shape the process!
2026-19284, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Orphan Drugs
The FDA is asking for public feedback on their plan to keep collecting info about orphan drugs—special medicines for rare diseases. This helps make sure drug makers follow rules and get the right approvals, keeping the process smooth and fair. Comments are open until October 21, 2026, and this review won’t cost anyone extra but keeps important protections in place.
Previous / Next Documents
Previous: 2026-15950, Certification Under Section 7045(b)(2)(A) of the Department of State, Foreign Operations, and Related Programs Appropriations Act, 2024 (SFOAA) (Div. F, P.L. 118-47), as carried forward by the Full-Year Continuing Appropriations Act, 2025 (Div. A, P.L. 119-4)
The U.S. government officially confirms that El Salvador, Guatemala, and Honduras are making real progress fighting corruption, improving justice, protecting human rights, and working with the U.S. to tackle crime and migration. These countries are also boosting their economies and security while promoting fair business practices. This certification keeps important U.S. support flowing in 2024 and 2025 to help these nations keep moving forward.
Next: 2026-15952, Procurement List; Proposed Additions and Deletions
The Committee is proposing to add service(s) to the Procurement List that will be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities, and delete product(s) previously furnished by such agencies.